SoloPak Obtains Rights to Ganite

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 2
Volume 4
Issue 2

ELK GROVE VILLAGE, Ill--SoloPak Pharmaceuticals, Inc. has signed an agreement with Sloan-Kettering Institute for Cancer Research to acquire the exclusive worldwide rights to gallium nitrate (Ganite), which was FDA approved in 1991 for the treatment of acute hypercalcemia in cancer patients and had been manufactured by Fujisawa USA (Deerfield, Ill).

ELK GROVE VILLAGE, Ill--SoloPak Pharmaceuticals, Inc. has signedan agreement with Sloan-Kettering Institute for Cancer Researchto acquire the exclusive worldwide rights to gallium nitrate (Ganite),which was FDA approved in 1991 for the treatment of acute hypercalcemiain cancer patients and had been manufactured by Fujisawa USA (Deerfield,Ill).

The agreement involves a grant of SoloPak equity to the Instituteand a commitment of funds from SoloPak to complete clinical trials.

Over the next 2 to 3 years, SoloPak plans to seek approval ofgallium nitrate for the treatment of chronic hypercalcemia andbone metastases in cancer patients, and to launch clinical trialsof the agent in Paget's disease and osteoporosis.

Articles in this issue
FTC Advised to List Tar and Nicotine Levels Directly on Cigarette Packages
Multidisciplinary Approach Urged For Pain Relief
FDA Approves New Indication for Neupogen: Chronic Neutropenia
Department of Labor Wants to Study Possible Occupation-Cancer Links
Undertreatment of Cancer-Related Pain May Be Tied to Physicians' Fear of Addiction to Drugs
Navelbine Is Now Available for Use in Inoperable Advanced Stage NSCLC
ASH Panel: How Many Hemotologists/Oncologists Are Enough?
Mammography Van Brings Breast Cancer Screening to the Workplace
FDA to Build $600 Million Campus
Finasteride Studied as Prostate Ca Preventive
Panel Fails to Recommend Taxotere as Treatment for Breast and Lung Cancer
Thrombopoietin Raises Platelet Counts in Animals
Major Cancer Centers Form Network to Negotiate With Insurers
ACS Panel on Prostate Cancer: Painful Skeletal Mets Require Special Management
Liposomal Tretinoin in Phase II/III Trials in Kaposi's Sarcoma Patients
Recent Videos
2 experts are featured in this series.
1 expert is featured in this series.
2 experts are featured in this series.
Dordaviprone was recommended at a dose of 625 mg orally once weekly for adults, and the recommended dosage is based on body weight for pediatric patients.
Extended follow-up for individuals with H3 K27M-mutated diffuse midline glioma may help explain the duration of response across patient subgroups.
Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, described the excitement of seeing novel molecules like antibody drug conjugates become more prominent.
Ronald Bleday, MD, credits a chronic pain clinic for consulting patients who may be at a greater risk for prolonged opioid use following surgery.
Related Content
Bridging therapy with talquetamab achieved “notable” disease control among patients with multiple myeloma in a retrospective study.

Talquetamab Bridging Strategy Appears Feasible in R/R Multiple Myeloma

Russ Conroy
August 20th 2025
Article

Bridging therapy with talquetamab achieved “notable” disease control among patients with multiple myeloma in a retrospective study.

Beyond the Tumor: Addressing Body Image in Oncology

Beyond the Tumor: Addressing Body Image in Oncology

Daniel C. McFarland, DO;Michelle Fingeret, PhD
August 18th 2025
Podcast

Daniel C. McFarland, DO, and Michelle Fingeret, PhD, discuss the issue of body image in patients with cancer.

Prior data from the STRESS-LUNG-1 trial introduced emotional distress as a “psycho-biomarker” for immunotherapy efficacy in non–small cell lung cancer.

Emotional Distress May Confer Worse Immunotherapy Outcomes in NSCLC

Russ Conroy
August 19th 2025
Article

Prior data from the STRESS-LUNG-1 trial introduced emotional distress as a “psycho-biomarker” for immunotherapy efficacy in non–small cell lung cancer.

Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma

Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
August 14th 2025
Podcast

The latest in first- and second-line therapies for bladder cancer, including trial data, AE management, and the role of molecular testing, were discussed in the latest Oncology Decoded podcast.

No minimal residual disease-negativity was observed with tuspetinib in patients with AML, including in a patient with more than 7 months of follow-up data.

Tuspetinib Exhibits Enhanced Efficacy in Diverse Newly Diagnosed AML Group

Roman Fabbricatore
August 19th 2025
Article

No minimal residual disease-negativity was observed with tuspetinib in patients with AML, including in a patient with more than 7 months of follow-up data.

Phase 3 findings may contribute to the selection of triplet or quadruplet therapies in newly diagnosed multiple myeloma via frailty-based assessments.

Carfilzomib Regimens Improve MRD Outcomes in Older, Fit NDMM Population

Russ Conroy
August 19th 2025
Article

Phase 3 findings may contribute to the selection of triplet or quadruplet therapies in newly diagnosed multiple myeloma via frailty-based assessments.